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Abstract
Birdshot Uveitis (Birdshot) is a rare eye condition that affects HLA-A29-positive individuals and could be considered a
prototypic member of the recently proposed ‘MHC-I (major histocompatibility complex class I)-opathy’ family. Genetic
studies have pinpointed the endoplasmic reticulum aminopeptidase (ERAP1) and (ERAP2) genes as shared associations
across MHC-I-opathies, which suggests ERAP dysfunction may be a root cause for MHC-I-opathies. We mapped the ERAP1
and ERAP2 haplotypes in 84 Dutch cases and 890 controls. We identified association at variant rs10044354, which mediated a
marked increase in ERAP2 expression. We also identified and cloned an independently associated ERAP1 haplotype (tagged
by rs2287987) present in more than half of the cases; this ERAP1 haplotype is also the primary risk and protective haplotype
for other MHC-I-opathies. We show that the risk ERAP1 haplotype conferred significantly altered expression of ERAP1
isoforms in transcriptomic data (n = 360), resulting in lowered protein expression and distinct enzymatic activity. Both the
association for rs10044354 (meta-analysis: odds ratio (OR) [95% CI]=2.07[1.58–2.71], P = 1.24 × 10(−7)) and rs2287987 (OR[95%
CI]: =2.01[1.51–2.67], P = 1.41 × 10(−6)) replicated and showed consistent direction of effect in an independent Spanish
cohort of 46 cases and 2103 controls. In both cohorts, the combined rs2287987-rs10044354 haplotype associated with
Birdshot more strongly than either variant alone [meta-analysis: P=3.9 × 10(−9)]. Finally, we observed that ERAP2 protein
expression is dependent on the ERAP1 background across three European populations (n = 3353). In conclusion, a
functionally distinct combination of ERAP1 and ERAP2 are a hallmark of Birdshot and provide rationale for strategies
designed to correct ERAP function for treatment of Birdshot and MHC-I-opathies more broadly.
Introduction
‘MHC-I(major histocompatibility complex class I)-opathy’ is a rela-
tively new term proposed to unify a group of severe inflam-
matory diseases, each characterized by strong association with
a unique MHC-I allele and shared immune characteristics (1).
Recent genetic association studies revealed a vast enrichment
for polymorphisms in the endoplasmic reticulum aminopeptidase
(ERAP) genes, ERAP1 and ERAP2, in patients with ankylosing
spondylitis (AS), psoriasis or Behçet’s disease (BD) (2–5). Impor-
tantly, in these conditions, ERAP is in epistasis with the risk
alleles of MHC-I allele. However, not all patients with AS or
BD carry a MHC-I risk allele, an observation that has provoked
discussions on this unifying concept (6,7) and whether it reflects
shared underlying disease etiology.
The mechanism through which ERAP function contributes to
MHC-I-opathies is still under intense discussion and the discov-
ery of the underlyingmechanism is hampered by several unique
characteristics of these specialized enzymes: the peptidases
ERAP1 and ERAP2 closely interact with MHC-I by contributing
to the generation and destruction of peptides considered for
presentation by MHC-I on the cell surface. This key function
indicates that aberrant peptide processing by ERAPmay be a root
cause for MHC-I-opathies (8). Similar to MHC-I, genetic diversity
of ERAP genes is conserved by balancing selection (9). Balancing
selection maintains ERAP2 deficiency in one-quarter of the
population (9) and drives the polymorphic ERAP1 gene to encode
various haplotypes (their protein products are also termed
‘allotypes’) (10), few of which paradoxically confer or reduce
risk for developing MHC-I-opathies (8). To date, ERAP haplotype
studies have been limited to the relatively more common MHC-
I-opathies (11–12). In contrast, Birdshot uveitis or Birdshot chori-
oretinopathy (from here on ‘Birdshot’) is a severe, extremely rare
eye condition (∼1–5 cases/500 000) (13,14) that is characterized
by enhanced IL-23-IL-17 pathway activation (15–17), and occurs
exclusively in HLA-A29-positive individuals (18). A previous
genome-wide association study in Birdshot highlighted strong
involvement of the ERAP region on chromosome 5q15 (19).
The unique (diagnostic) prerequisite of HLA-A29 (20) and ERAP
association may classify Birdshot patients within the MHC-I-
opathy cluster and, thus, provide an attractive model to define
the genetic architecture of this superfamily of conditions (18).
Therefore, we mapped ERAP1 haplotypes and other key vari-
ants at 5q15 across a Dutch discovery cohort and validated our
findings in a Spanish replication cohort. We interrogated the
downstream implications of associated variants using transcrip-
tomic data, molecular cloning and functional assays.
Results
Two independent variants at 5q15 associate with
Birdshot
To test for genetic variants that associate with Birdshot, we
obtained genotype data for 13 key variants at 5q15 in 84 cases
and 890 controls from the Netherlands (Supplementary Table
1). Using a logistic regression model, adjusted for sex and the
top two principle components, we identified a top association at
the T allele of rs10044354 in leucyl and cystinyl aminopeptidase
(LNPEP) (odds ratio (OR) = 2.42[95% CI: 1.69–3.45], P = 1.21 × 10−6,
Figure 1 and Supplementary Table 1).We accounted for the effect
of rs10044354 using conditional analysis, and identified the C
allele of rs2287987 (encoding valine at amino acid position 349)
in ERAP1 as a secondary (independent) association to Birdshot
(OR = 1.99 [95% CI: 1.36–2.90], P = 3.97 × 10−4, Fig. 1). Due to link-
age disequilibrium (LD), several other single nucleotide polymor-
phisms (SNPs) across the locus also showed strong association,
but conditioning on rs2287987 in ERAP1 removed the remainder
of the association signal in the region (Supplementary Table 1).
We sought to replicate the associations with rs2287987 and
rs10044354 using a set of independent samples drawn from an
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Figure 1. Association and conditional testing for the 13 polymorphisms at 5q15. (A) Initial association testing mapped the strongest association to rs10044354 in LNPEP
(Dark red). (B) Conditioning on rs10044354 revealed independent association for the C allele of rs2287987 (amino acid position 349 in ERAP1) and variants in tight LD
(rs10050860 and rs17482075 in dark blue) in ERAP1. (C) Conditioning on both rs10044354 and rs2287987 removed the bulk of the signal (rs30187, P = 0.05). Plot framework
was generated by LocusZoom (53) and edited for graphical purposes.
independent Spanish cohort of 46 cases and 2103 controls. Both
associations replicated (Table 1 and Supplementary Table 1) and
show consistent direction of effect (meta-analysis, rs10044354,
OR [95% CI: = 2.07[1.58–2.71], P = 1.24 × 10−7; meta-analysis
rs2287987, OR [95% CI]: = 2.01[1.51–2.67], P = 1.41 × 10−6).
Interestingly, the combined haplotype rs2287987-rs10044354
showed disease association exceeding the association for
each individual SNP in both cohorts (Supplementary Table 2).
The strongest association mapped to the protective haplotype
rs2287987-T/rs10044354-C (meta-analysis, OR [95% CI]: =0.39
[0.30–0.55],P = 3.9 × 10−9), closely followed by the risk hap-
lotype rs2287987-C/rs10044354-T (OR [95% CI]: = 2.75 [1.92–
3.92], P = 2.6 × 10−8), the latter present in 50% of all 130
cases and 26% of all 2993 controls. The frequency of the
CT-risk haplotype (0.24 in Dutch cases and 0.19 of Spanish
cases) is ∼5–6x less common in African (0.027) and Asian
(0.021) populations compared with the European population
(0.13, Fig. 2A).
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Figure 2. Birdshot associated variants affects ERAP1 and ERAP2 expression and function. (A) The frequency of the rs2287987-rs10044354 haplotypes inDutch and Spanish
cases and controls, and the EUR, EAS and AFR super populations of the 1000 Genomes project (48). The frequency of the haplotypes is indicated as the percentage of
all haplotypes for each population. (B) We tested for association of rs2287987-rs10044354 genotypes in 129 HLA-A29-positive cases and 439 HLA-A29-positive controls
in the combined Dutch and Spanish samples. ORs (and 95% confidence intervals) for each genotype combination were calculated relative to lowest risk genotype: the
rs2287987-TT/rs10044354-CC (set to an OR of 1). The risk allele (red) and protective alleles (green) are highlighted. (C) Expression data for transcripts at 5q15 in 360
lymphoid cell lines from the European populations from the GEUVIDAS consortium (48). Red lines indicate the median expression. (D) The lead SNP rs10044354 is a
strong eQTL for ERAP2 independent of rs2248374 (details eQTL analysis in Supplementary Table 4). (E) The Birdshot-associated rs2287987 is associated with changes in
the twomajor ERAP1 transcripts. (F) QuantitativeWestern blot analysis of the protein expression of ERAP1 in HLA-A29-positive cell lines according to the distribution of
rs2287987 (more details see Supplementary Fig. 4). (G) Hydrolysis [expressed as relative fluorescent units of the substrate Leu-AMC by immunoprecipitated ERAP1 protein
from lymphoid cell lines homozygous Hap10 (risk haplotype), homozygous Hap2 (protective haplotype) and a heterozygous donor for these two ERAP1 haplotypes.
Error bars indicate the mean (range) of three independent experiments.
Since Birdshot is associated with HLA-A29, we investigated
the association for the rs2287987-rs10044354 haplotype in
the context of HLA-A29 status in the combined 129 HLA-
A29-positive cases and 439 HLA-A29-positive controls (15% of
controls). ORs for each haplotype’s association to Birdshot were
calculated relative to the haplotype carrying the two lowest
risk genotypes: rs2287987-TT-rs10044354-CC. In the HLA-A29-
postive population, only genotypes that harbor risk alleles
from both rs2287987 and rs10044354 associated with Birdshot
(P < 1.49 × 10−4), with the strongest association observed for
the rs2287987-CC-rs10044354-TT genotype (OR [95% CI]: = 41.4
[10.08–170.08], P = 2.4 × 10-7) (Fig. 2B). Considered collectively,
our association testing demonstrates that rs10044354 in LNPEP
and rs2287987 in ERAP1 explained the bulk of the association
with Birdshot at 5q15 and that combinations of these ERAP
variants significantly increase the risk in the HLA-A29-positive
population.
ERAP1 Hap10 is associated with Birdshot
Common ERAP1haplotypes have been previously linked toMHC-
I-opathies (8). Considering 10 non-synonymous variants (i.e. 10
amino acid positions) in ERAP1 together (21), we identified eight
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common (frequency >1%) haplotypes (Table 1). The Birdshot-
associated C allele of rs2287987 (349V) resides in the ERAP1
haplotype previously labelled ‘Hap10’ (21). Indeed, testing for
association of phased haplotype data revealed that Hap10 was
associated with Birdshot and replicated in both cohorts (meta-
analysis OR = 1.99 [95% CI: 1.49–2.65], P = 2.88 x 10−6, Table 1).
We also noted that Hap2 was less frequent in cases (Table 1).
Sixty-three percent of Dutch cases and 46% of Spanish cases had
at least one copy of Hap10 compared with 37.2% and 34.7% of
controls, respectively (Supplementary Table 3).
The primary association signal at 5q15 associates with
increased ERAP2 expression
Next, we aimed to predict the local transcriptional regulation of
the Birdshot-associated loci at 5q15 using RNA-sequencing data
from 360 individuals of European ancestry and 82 individuals
from African ancestry. We used lymphoid cell lines due to their
high gene and protein expression of ERAPs and representation
of expression quantitative trait loci (eQTLs) cis effects of blood
cell populations (Supplementary Fig. 6). We applied a linear
mixed model controlling for sex, ancestry, and batch to model
if the SNPs imposed eQTLs effects on transcripts encoded by
5q15 (Fig. 2C); The leading SNP (rs10044354) in LNPEP was not
associated with the expression of its major transcript (Supple-
mentary Table 4). We extracted common missense and splice
region variants of LNPEP in high LD with rs10044354 from the
European populations of the 1000 Genomes (22) and identified
the splice region variant rs3836862 (r2 > 0.96 in five popula-
tions) located near the exons encoding the zinc-binding motif
of the enzyme and is predicted to influence splicing. However,
we detected no evidence for potential alternative splicing of
LNPEP by this variant in lymphoid cell lines (detailed experi-
ments provided under Supplementary Fig. 5). Correcting for the
expression of ERAP2 mediated by rs2248374, we found the risk
allele of rs10044354 to be strongly associated with ERAP2 in
samples from European ancestry. Further, this allele associated
to a 235% increase in expression of ERAP2 independent from
rs2248374 (Incidence rate ratio (IRR2) [95% CI] = 3.35[2.76–4.06],
P = 3.48 × 10−33, Supplementary Table 4 and Fig. 2D). In line with
this, conditioning on rs2248374 in ERAP2 in the 130 cases and
2993 controls combined,we found the association for rs10044354
with Birdshot to be independent from rs2248374 (P = 9.1 × 10−4).
ERAP1 risk alleles reside in a relatively low expressed
haplotype
The Birdshot risk variant rs2287987 (349V in ERAP1) is in
near complete LD (r2 = 0.99) with rs10050860 (575N in ERAP1,
P = 1.46 × 10−6 for association with Birdshot). The SNP
rs10050860 was recently suggested to represent a splice
interfering variant (rs7063), which was linked to changes in
the proportion of expression of two major ERAP1 isoforms
(23). We explored the rs7063 variant using rs1057569 (r2 = 1).
Indeed, we observed strong association between the rs1057569
genotype and the expression of the twomajor ERAP1 transcripts
in samples of European ancestry (Supplementary Table 4). This
variant is also among the top eQTLs for ERAP1 in lymphoid
cell lines investigated in the Genotype-Tissue Expression
(GTEx) project (Supplementary Fig. 7). The rs2287987 is in
moderate LD with rs1057569 (r2 = 0.53 in the combined 2993
controls) and associated with ∼50% change in expression
of the major ERAP1 isoform (Supplementary Table 4 and
Fig. 2E), which results in ∼5x lower cumulative levels of ERAP1
protein in HLA-A29-positive individuals homozygous for the
C allele of rs2287987 (Fig. 2F). However, the eQTL effects of
rs2287987 on ERAP1 transcripts were completely abrogated once
adjusted for rs1057569 (Supplementary Table 4). Therefore, we
tested whether the rs2287987 disease signal was mediated by
rs1057569. Conditioning on rs1057569, we found the rs2287987
signal to be modestly affected (pmeta = 4.61 × 10-4), while
conditioning on rs2287987 neutralized the signal (pmeta = 0.39).
These results indicate that the association signal at rs2287987
represents a signal beyond the association with the splice
interfering variants in ERAP1. We note that the A allele of
rs1057569 (T allele of rs7063) associated with low expression
of ERAP1 protein is present in >90% of ERAP1 haplotypes
that encode Hap10 and Hap6, and <10% of the other common
ERAP1 haplotypes in controls. In the Nigergian (YRI) population
(n = 82), the rs2287987 genotype is not in LD with rs1057569
(r2 = 0.009), and not linked to ERAP1 expression (transcript
ENST00000443439.6, IRR2 [95% CI] = 0.93[0.65–1.32], P = 0.68).
Full-length ERAP1 sequencing of the risk haplotype
We cloned the full-length coding sequence of ERAP1 from two
patients that were heterozygous or homozygous for Hap10 to
reveal the amino acid residues for additional reported amino
acid positions in ERAP1 (24). Analysis of the coding sequence
revealed that both copies (based upon nine individual clones)
of Hap10 encoded the ancestral alleles for additional reported
amino acid positions (Supplementary Table 5). All detectable
transcripts contained a C-terminus identical to the 19-exon
transcript ERAP1-202 (ENST00000443439).
Disease-associated ERAP1 displays distinct enzymatic
activity.
Considering the association of rs2287987 exceeded variants that
govern ERAP1 expression and that rs2287987 has previously
been shown to affect trimming properties of recombinant ERAP1
(25,26), we assessed the relative enzymatic activities of ERAP1
haplotypes in vitro. We compared normalized concentrations of
ERAP1 protein precipitated from lymphoid cell lines of patients
and controls that carry the Hap10 and Hap2, the latter haplo-
type showing evidence for protection against Birdshot (Table 1).
Total cellular ERAP1 protein appeared to have slower rates for
enzymatic trimming of the archetypical fluorogenic substrate
L-Leucine-4-methylcoumaryl-7-amide (Leu-AMC)with each sequen-
tial increase in Hap10 compared with homozygous carriers of
Hap2 (Fig. 2G). These results confirm that changes of enzymatic
properties in ERAP1 are mediated by haplotypes that carry the
C allele of rs2287987 (i.e. Hap10), thereby governing functional
consequences for patients with Birdshot.
Non-random distribution of ERAP1-ERAP2 haplotypes
in the European population.
ERAP2 encodes two common haplotypes (9): the A allele of
rs2248374 tags Haplotype A [HapA], which encodes a canoni-
cal protein, while the G allele tags HapB, which usually lacks
functional protein (Supplementary Fig. 8). Since ERAP1 is pos-
tulated to be complemented by ERAP2 in trimming peptides (27),
we hypothesized that the expression of ERAP2 protein could be
dependent on the ERAP1 haplotype and that this relationship
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Figure 3. Non-random distribution of the ERAP2-protein coding haplotype
across common ERAP1 haplotypes. Tenmissense variants in ERAP1 encode eight
discrete and common haplotypes, while ERAP2 encodes a common protein-
coding haplotype (HapA tagged by the A allele of rs2248374) and non-coding
haplotypes (tagged by the G allele). Each chromosome 5 harbors one ERAP1
haplotype and one ERAP2 haplotype. Using phased ERAP1-ERAP2 haplotype data
of 890 Dutch controls (1780 phased haplotypes) and 2103 Spanish controls (4206
phased haplotypes), we outlined the percentage of HapA per ERAP1 haplotype
on the same chromosome. Error bars indicate the 95% confidence interval based
upon 20 000 bootstrap samples. Frequency ofHapA of ERAP2 for each of the ERAP1
haplotypeswas considered non-random if the observed frequency deviated from
an expected 50% using an exact binominal test with [A or G rs2248374 for 8 ERAP1
haplotypes = 0.05/16] P < 2.5 × 10-3 in both the Dutch and Spanish populations
with consistent direction of effect. ERAP1 haplotypes that fulfilled these criteria
are highlighted by asterisks (for summary statistics see Supplementary Table 6).
As a reference, we plotted the ERAP1-ERAP2 haplotype data for the 360 samples
from the CEU, FIN, GBR and TSI populations from the 1000 Genomes sample
collection used for functional investigation in this study (48).
should be evident in the population. To explore this hypoth-
esis, we used phased genotype data of three populations of
3353 controls to test whether the frequency of HapA of ERAP2
differed between ERAP1 haplotypes encoded along the same
chromosome.We observed a non-random distribution of ERAP2-
HapA across the ERAP1 haplotypes for each European population
(Fig. 3 and Supplementary Table 6). This reflects the complex
pattern of LD (D’) between non-synonymous variants in ERAP1
and rs2248374 in ERAP2 (Supplementary Fig. 9). A similar non-
random distribution was observed for ERAP1 haplotypes con-
sidering five non-synonymous variants in ERAP1 (12) (Supple-
mentary Fig. 10). This demonstrates that the co-occurrence of
functional ERAP2 protein is dependent on the ERAP1 haplotype
background.
Discussion
We defined the common ERAP1 and ERAP2 haplotype structure
in Birdshot, confirmed the genetic association with rs10044354
(19) and showed that despite strong LD between rs10044354
and splice region variant rs2248374 in ERAP2, the strong eQTL
effects of rs10044354 on ERAP2 expression are independent from
rs2248374. This finding suggests that a change in expression,
and not merely the presence of ERAP2, confers risk for Birdshot
and other ERAP2-linked conditions (28). Thus, future treatment
strategies to dampen ERAP2 expression may complement cur-
rent research efforts focused on the pharmacological inhibition
of its aminopeptidase activity (29).
We revealed a second independent association for rs2287987
in ERAP1, an SNP that nearly always resides in the common
ERAP1 haplotype Hap10 (21). The rs2287987 risk genotype
is accompanied by changes in ERAP1 transcript levels and
lower protein expression as a result of LD with rs1057569, a
strong eQTL for ERAP1 (Supplementary Fig. 6). The functional
implications of ERAP1 expression need further investigation,
especially since the risk genotype linked to AS results in
increased ERAP1 expression (23). However, the association with
rs2287987 was independent from rs1057569, suggesting disease
modifying effects beyond the expression of ERAP1. Indeed,
we ascertained that the Birdshot-associated allele of rs2287987
(349V located near the zinc-bindingmotif of the enzyme) resides
in an haplotype that within cells exhibits distinct enzymatic
activity and our data support previous studies indicating that
Hap10 can be considered functionally antagonistic to Hap2
and Hap1 (24,26). Also, direct comparison by molecular cloning
revealed that Hap10 in Birdshot and a previously investigated 15
non-synonymous variant (i.e. affecting amino acid residues)
ERAP1 haplotype, termed ∗001, represent identical ERAP1
haplotypes (10,24). The ∗001 (Hap10) was previously shown
to provide suboptimal peptide cargo for MHC-I, by reduced
trimming of peptides (10,24). Therefore, Hap10 may confer risk
by incomplete destruction of immunogenic epitopes that bind
HLA-A29. Eye tissues of Birdshot patients are infiltrated by
CD8+ T cells, but to date, evidence for their direct involvement
is lacking (18). ERAP1 and ERAP2 may perhaps also influence
T or NK cells function via Killer immunoglobulin-like receptors, a
class of immune receptors that interact with MHC-I that have
been genetically linked to Birdshot (30).
Hap10 is also the major risk ERAP1 haplotype for patients
with BD and is highly protective against AS (11,12). Hap10
is associated with BD assuming a recessive model (Birdshot,
pmeta-recessive = 9.81 × 10−5). Hap1/Hap2 are risk haplotypes
for AS and psoriasis (8,12), while being protective for BD and
Birdshot. Therefore, Hap10 and Hap2 of ERAP1 play a central
role for patients within the MHC-I-opathy cluster: patients with
psoriasis have an increased risk of uveitis (31). Patients with AS
and BD often have uveitis (11,42), and the ERAP1 associations are
much stronger in cases that developed uveitis compared with
cases with systemic disease alone (2,32). Although HLA-A29
is also common in some non-European populations (∼7–14%
of Caucasian populations is HLA-A29 positive) (18), Hap10 and
particularly the Hap10-ERAP2 (rs2287987-rs10044354) haplotype
are less common in Asian and African individuals compared
with European and, as we show, if present may exhibit different
functional effects on ERAP1, which may explain why Birdshot
primarily affects patients of European descent (18).
Although 90% of all cases carried either a risk allele for
rs2287987 or rs10044354, 50% of all cases were positive for
the combined haplotype. A proportion of Birdshot patients
may have self-limiting disease, while others will develop
irreversible retinal dysfunction and blindness (13). It will be
interesting to evaluate the potential relation between ERAP
haplotypes and clinical outcome (e.g. electroretinography)
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in follow-up studies. This was not possible because of the
relatively limited sample size, owing to low prevalence of
this rare disease (13,14). This limitation also hampered the
investigation for association with other SNPs with evidence
for more moderate effect size (e.g. rs30187). Regardless, the
strongest associations for Birdshot include the rs2287987-
rs10044354 haplotype and HLA-A29, a triad of loci that encode
functionally tightly related proteins of the class I antigen
presentation pathway and warrants further investigation
into antigen presentation in human uveitis. Whether ERAP1
and ERAP2 contribute to disease by direct interaction in
the endoplasmic reticulum is not known (43–45). In the
absence of ERAP2 protein, cells with distinct ERAP1 haplo-
types show substantial differences in HLA-A29 peptidome
composition, which demonstrates that ERAP1 is able to
directly influence HLA-A29 (43). We recently showed that
ERAP2 increases the number of 9-mer peptides presented by
HLA-A29 (36). This suggests that some peptides bound by
ERAP2 may be protected from destruction by ERAP1, which
will be further facilitated in a hypoactive ERAP1 background
(i.e. Hap10). These results favor our hypothesis that a limited
set of uveitogenic peptides drive T cell mediated pathology in
Birdshot (18). However, ERAP2 has different peptide preferences
compared with ERAP1 (27,29) and MHC-I peptidome studies
support separate contributions of Hap10 and ERAP2 in manipu-
lating the peptide composition presented on the cell surface (35).
This reflects the lack of LD between the protein-coding ERAP2
haplotype and MHC-I-opathy linked Hap10 and Hap2/Hap1
in the European populations investigated. However, ERAP2
protein expression more often occurs in ERAP1 haplotypes
Hap8 and Hap7 (and perhaps Hap3) background, as a result
of LD (D’) between SNPs including rs3734016 and rs26618, and
rs2248374 (Supplementary Fig. 9). The lack of detailed MHC-
I data hampered further investigation of this phenomena,
because ERAP2 may not equally contribute to the peptidome
of each MHC-I molecule (26,34). However, this would demand a
large population study with sufficient power to investigate the
ERAP1-ERAP2 haplotypes for distinct MHC-I haplotypes. Such
studies will also be key to advance our understanding of ERAP
function in inflammation, cancer and less explored fields such
as transplantation biology and vaccine efficacy studies.
The original concept of the MHC-I-opathy aims at clustering
subsets of clinical phenotypes on the basis of one or multiple
unifying molecular fingerprints (1). Here, we explicitly refer to
the subgroup of patients that carry risk MHC-I alleles (and ERAP
variants in epistasis) when referring to ‘MHC-I-opathy’ patients.
Our results in Birdshot further substantiate the existence of
such concept. We envision that molecular reclassification based
on a patient’s MHC-I and ERAP haplotype may improve clinical
decision making as well as drug discovery (e.g. ERAP inhibitors)
in the near future. Emerging studies explore this concept, those
of which that have linked clinical response to ERAP variants
(37–40). Ultimately, understanding how to pharmacologically
influence ERAP function (41) may lay the foundation for the
design of effective therapeutic strategies to correct ERAP
function in accordance with the patient’s molecular fingerprint
to tailor the treatment of MHC-I-opathy patients specifically.
Materials and Methods
5q15 variant and haplotype testing in Dutch and
Spanish cohorts
This study was performed in compliance with the guidelines of
the Declaration of Helsinki and has the approval of the local
Institutional Review Board (University Medical Center Utrecht).
Genotype data for 13 key variants at 5q15 (Supplementary Table
1) and HLA-A29 status from 84 Dutch cases and 890 Dutch con-
trols from European ancestry were obtained from a previously
described discovery collection and the Genome of the Nether-
lands Project (GoNL) release 4 (19,42). The number of samples
is slightly fewer than the Dutch discovery cohort because some
samples no longer met the criteria for Birdshot Uveitis (e.g.
presence of systemic disease) or failed to pass quality control
requirements. Imputation of untyped SNPswas conducted using
the GoNL and 1000 Genomes Project Phase 3 data (imputed SNPs
with info > 0.95) (43). Disease association testing was performed
with PLINK v1.07 (44) using a logistic regressionmodel correcting
for the top two principal components and sex (Supplementary
Fig. 1). For replication, the genotype data (n= 13) (Supplementary
Table 1) and HLA-A29 status were extracted from 46 Spanish
cases and 2103 Spanish controls from a previously described
non-infectious uveitis collection (45) and tested with a logis-
tic regression model (replication was defined as Bonferroni-
corrected P-value for two LD blocks at 5q15 = 0.025). Meta-
analysis of Dutch and Spanish cohorts was performed using
inverse variance-weighted meta-analysis (46). Common ERAP1
haplotypes (based on 10-non-synonymous variants,which occur
in >1% of controls, see Table 1 and Supplementary Fig. 2) were
phased using PLINK. The estimated haplotype frequencies for
the identified eight common ERAP1 haplotypes matched the
frequency of haplotypes estimates of genotype data by SHAPEIT2
(considered the most accurate method available) (47). Therefore,
the phasing accuracy of PLINK was considered sufficient for
ERAP1 haplotype association testing using logistics regression
(Supplementary Fig. 3). The total testing burden for SNP asso-
ciation was estimated at ([13 variants + 8 ERAP1 haplotypes] × 3
models + 4 rs2287987-rs10044354 haplotypes = 67 independent
tests) a 1% type I error rate with P < 1.49 × 10−4, which was
used as a threshold to prioritize SNP associations calculated in
the discovery and meta-analysis. We tested for the rs2287987-
rs10044354 haplotype in the 129 HLA-A29-positive Dutch and
Spanish cases and 439 HLA-A29 positive Dutch and Spanish
controls using a logistic regression model using the glm func-
tion n R (v3.3.2) with the command ‘family = binomial’. The
OR for each possible genotype was calculated by exponenti-
ating the coefficient from the logistic regression. The low risk
rs10044354-CC/rs2287987-TT genotype was set as the baseline
(OR = 1) and the other genotype combinations were coded
according to a series of dichotomous indicator variables. P-
values from the logistic regression below P < 1.49 × 10−4 were
considered significant.
Investigation of the distribution of ERAP1 and ERAP2
haplotypes in European populations
The major haplotype of ERAP2 is under balancing selection,
where theG allele rs2248374 tags a non-protein coding haplotype
(HapB) and the A allele of rs2248374 tags the protein-coding
haplotype (HapA) (9). The frequency of the A allele of rs2248374
co-occurring on the same chromosome with each of the eight
common ERAP1 haplotypes was determined in the 890 Dutch
and 2103 Spanish controls using phased haplotype data using
SHAPEIT2 (47), and phased haplotype data were obtained for the
British [GBR], Finnish [FIN], Utah residents with Northern and
Western European ancestry [CEU] and Tuscany [TSI] populations
from the GEUVIDAS consortium (48). The 95% confidence inter-
vals of the observed frequencies were estimated using bootstrap
sampling (n = 20 000).We used a two-sided exact binominal test
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to assess whether the observed frequencies were non-random
(deviation from a test probability of 0.5 or the hypothesis that
ERAP2 co-occurs in 50% of any particular ERAP1 haplotype).
Frequency distribution of ERAP2 for each of the ERAP1 haplo-
types was considered non-random at [A or G rs2248374 for eight
ERAP1 haplotypes = 0.05/16] P < 2.5 x 10−3 in both the Dutch and
Spanish populations (with consistent direction of effect).
Statistical framework for 5q15 eQTL analysis
To investigate the transcriptional regulation of the variants at
5q15, RNA-sequencing data from the GEUVADIS consortium of
360 lymphoid cell lines of European ancestry and 82 African
samples (48) were extracted via the recount2 package, a resource
for expression data for uniformly processed and quantified RNA-
sequencing reads from >70 000 human samples (49). Transcript-
level counts of all samples of the GEUVADIS study were scaled
using the scale counts function in the recount2 package to
take into account differing coverage between samples. Data
corresponding to reported transcripts from ERAP1, ERAP2 and
LNPEP (n= 25 using Ensembl (22) transcript IDs)were extracted for
all samples, of which 4 transcripts were sufficiently expressed
and considered for testing the effect of genotype on tran-
script expression (ERAP1∼201, ENST00000296754.7; ERAP1∼202,
ENST00000443439.6; ERAP2∼202,ENST00000437043.7; LNPEP∼201,
ENST00000231368.9). The phased genotype data were obtained
via the Ensembl portal (22). To interrogate the effect of genotype
on local transcript expression, we fitted a generalized linear
mixed model (GLMM) using a negative binominal fit of the count
data and logarithmic link using the lme4 package in R (v3.3.2)
(50), with a fixed effect of patients sex and random effects of
laboratory (n = 7) and population (n = 5) of the 1000 Genomes
project (formula 1). For pairwise conditioning, the genotype
of the studied SNP was added as a covariate into the GLMM
(formula 2):
(1): glmer.nb(expression ∼ genotype + sex + (1|Laboratory) +
(1|Population))
(2): glmer.nb(expression ∼ genotype + sex + conditional SNP
genotype + (1|Laboratory) + (1|Population)).
Genotypes were ranked using their imputed dosage value
(a number from 0 to 2, indicating the number of risk alleles
for each SNP; Supplementary Table 1) adapted from a previous
method (23). Patients homozygous for the G allele of rs2248374
(n = 94) were removed to fit a model for ERAP2 expression in
HapA-positive individuals. The incident rate ratio (IRR) is the
exponential of the coefficient returned from the GLMM. We
used IRR2 as the metric for change in transcript expression (23),
which is conceptually similar and close to the fold change in
expression (mean count of the transcript) between individuals
homozygous for the protective over individuals homozygous for
the risk alleles. IRR2 < 0.60 or >1.30 (>30% change in expression)
were prioritized for reporting as biologically relevant. Effect size
metrics of eQTL analysis from lymphoid cell lines and whole
blood from the GTEx project Phase 2 for genes at 5q15 were
obtained via the GTEx portal (51).
Western blot analysis of ERAP1 and ERAP2
Human lymphoid cell lines were generated from peripheral
blood of Dutch cases recruited at the Departments of Oph-
thalmology at the University Medical Center Utrecht and
Radboud University Medical Center, the Netherlands. Cells
were grown in Roswell Park Memorial Institute 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum
and antibiotics. The following HLA-A29-positive cell lines were
obtained from the National Institute of General Medical Sciences
Human Genetic Cell Repository at the Coriell Institute for
Medical Research: GM19310, GM19397, GM19452, HG00096,
HG00113, HG00116, HG01082. Protein lysates (10 μg/lane) of
>2 × 106 cells were separated on a 4–20%Mini-PROTEAN TGX gel
(Bio-Rad Laboratories, Richmond, CA, USA) and transferred
to a Polyvinylidene difluoride membrane and detected using
antibodies to ERAP1 and ERAP2 (AF3830, AF2334, both R&D
Systems), and α-tubulin (T6199, Sigma), and secondary anti-
bodies conjugated to Horseradish Peroxidase. The ratio of the
intensity of the ERAP1 over α-tubulin band was calculated using
Image Lab 5.1 (Bio-Rad Laboratories) and grouped according
to the distribution of rs2287987 genotype. Details on the
Western blot analyses of lymphoid cell lines are outlined under
Supplementary Fig. 4.
LNPEP sequencing
We sequenced exon 5–8 of LNPEP from total RNA (cDNA) in
steady-state or 24 h stimulated [TLR7/8 (R848) and TLR9 (CpG-
B ODN 2006) agonists] lymphoid cell lines of four individuals
homozygous for the deletion and four homozygous for the
C allele of rs3836862, as determined by sanger sequenc-
ing. Detailed methods and used primers are provided in
Supplementary Fig. 5.
Full-length ERAP1 cloning and sequencing
RNA was isolated from >2 × 106 cells of two patients with
Quick-RNATM MiniPrep kits (Zymo Research, Irving, CA,USA) and
immediately used to generate cDNA with the Transcriptor High
Fidelity cDNA synthesis kit (Roche, Mannheim, Germany) using
the provided random hexamere primers. ERAP1 was directly
amplified from cDNA as described (10). The product was gel-
purified, and cloned into the blunt-end cloning vector, pCR-
Blunt II, using the Zero Blunt® TOPO® PCR Cloning kit (Life
Technologies) or cloned into StarGate® pESG-IBA vectors (IBA
Lifesciences), and sequenced.
Cellular ERAP1 enzymatic activity
Total cellular ERAP1 was immunoprecipitated with anti-
ERAP1 (5 ug/mL, AF2334, R&D Systems) antibody and protein
G-sepharose beads as described (52). Equivalent concentrations
of protein samples (normalized by Bradford assay) of purified
ERAP1 were incubated with 50 μM Leucine-aminomethyl-
coumarin and fluorescent intensity was followed for 30 min
with excitation at 365/380 nM and emission at 440/450 nm.
Supplementary Material
Supplementary Material is available at HMG online.
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